Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.
BACKGROUND
Selective serotonin reuptake inhibitors (SSRIs) have gained wide acceptance in the treatment of mental disorders in pregnant women, but there seems to be an increased risk for neonatal adaptation problems after exposure to SSRIs in late pregnancy. We aimed to investigate the perinatal sequelae of infants exposed to SSRIs during their fetal life and the relationship of these symptoms to the cord blood monoamine and prolactin concentrations.


METHODS
We conducted a prospective, controlled, follow-up study with 20 mothers taking 20 to 40 mg/d of either citalopram or fluoxetine for depression (n = 10) or panic disorder (n = 10) and their infants and 20 matched controls not receiving psychotropic medication for confounding obstetric characteristics. Maternal cord blood and infant citalopram, fluoxetine, and norfluoxetine, cord blood monoamine and metabolite, and prolactin concentrations were measured. The newborns underwent standard clinical examination and specific assessment of serotonergic symptoms during the first 4 days of life and at the ages of 2 weeks and 2 months.


RESULTS
There was a statistically significant (P =.008, V = 15, n = 20 for both groups), 4-fold difference in the serotonergic symptom score during the first 4 days of life between the SSRI group and the control group. The SSRI-exposed infants had significantly lower cord blood 5-hydroxyindoleacetic acid (5-HIAA) concentrations (P =.02, t31 = 2.57) compared with the control group. A significant inverse correlation (rs = -0.66, P =.007, n = 15) was seen between the serotonergic symptom score and the umbilical vein 5-HIAA concentrations in the SSRI-exposed but not the control infants.


CONCLUSIONS
Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
Laine
Kari
K
Department of Pharmacology and Clinical Pharmacology, University of Turku and Turku University Central Hospital, Turku, Finland. karlai@utu.fi
Heikkinen
Tuija
T
Ekblad
Ulla
U
Kero
Pentti
P
D000328:Adult; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy; D005260:Female; D005312:Fetal Blood / Q000737:chemistry*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood*; D007231:Infant, Newborn; D008297:Male; D018811:Maternal Exposure; D008431:Maternal-Fetal Exchange; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy*; D016584:Panic Disorder / Q000097:blood / Q000188:drug therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood*; D020230:Serotonin Syndrome / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D006897:Hydroxyindoleacetic Acid; D011388:Prolactin; D017367:Selective Serotonin Reuptake Inhibitors